All In Biotech

Drug Trial Radar · NCT03240809

An Open-label, Single-dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Brodalumab in Pediatric Subjects

An Open-label, Single-dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Brodalumab in Pediatric Subjects (6 to < 18 Years Old) With Severe Plaque Psoriasis

Last checked: Nov 20, 2026Latest source record: Sep 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

2

Actual

Start

Jan 24, 2020

Primary completion

Dec 2028

Study completion Jun 2029

Sponsor

Lead sponsor
Bausch Health Americas, Inc.Industry
Sponsor type
Industry
First posted
Aug 7, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 6 years, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

An Open-label, Single-dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Brodalumab in Pediatric Subjects

Conditions

  • Psoriasis

Interventions

  • BrodalumabBiological

    140 mg SC dose

  • BrodalumabBiological

    70 mg SC dose

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. maximum observed concentration (Cmax)Time frame: 29 Days

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Bausch Site 003

    San Diego, California

  • Bausch Site 002

    Miami, Florida

  • Bausch Site 004

    Miami, Florida

  • Bausch Site 005

    Henderson, Nevada

  • Bausch Site 001

    Las Vegas, Nevada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.